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1. Abstract 
Objective: To present the long-term follow-up results after brainstem glioma (BSG) 
surgery at the University Hospital Zurich including low-grade gliomas (LGG) over more 
than 4 decades and to trace historical changes in BSG surgery with a special focus on 
LGG. 
Methods: I searched the archives of the neurosurgery department for BSG surgeries 
including LGG between 1937 and 2007. The directors of the department in this time span 
were the surgeons H. Krayenbühl, G. Yasargil and Y. Yonekawa. Histological information 
was added from the department of pathology. Follow-up data was completed from the 
community registration offices and patient records in the department of neurosurgery. 
Results: In total I found 124 patients with BSG surgeries in the data collection including 64 
patients with LGG. The median age at surgery was lower in the era Yasargil (18y, N=77) 
than in the era Yonekawa (30y, N=27, p = 0.02). Operated LGG patients were higher 
presented in the era of Yasargil than in the era Yonekawa (53/77 vs. 13/27, 
crosstabulation chi2 p=0.055). Follow-up (FU) of the LGG patient group was available in 
47 patients (73.4%) with a median of 9 years (range 0-33years). 18 patients (38%) had a 
FU >10 years and 10 patients (21.3%) a long-term FU >20 years. There was only one 
documented death in one patient 27 years after surgery. Median progression free survival 
(PFS) was 27 years with no significant difference between patients operated in the era 
Yonekawa (median PFS 6 years) or Yasargil (median PFS 27 years) (p=0.387). 
Conclusion: In this study we were able to demonstrate long-term FU with a high overall 
survival and PFS in LGG patients after BSG surgery. As the University Hospital Zurich was 
among the first to initiate BSG surgery, we could trace the paradigms of BSG surgery from 
its onset in a single center study. 
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2. Introduction 
Brainstem gliomas (BSG) constitute approximately 1% of adult brain tumors and 
10% of all pediatric brain tumors and are the most common neoplasm occurring in the 
brainstem.1 BSG have historically been one of the most difficult cancers to treat and were 
once uniformly discounted as surgically unresectable lesions.2 In the times before 
computed tomography (CT), magnetic resonance imaging (MRI) these lesions were 
summarized as malignant tumors regardless of specific histology due to their location 
itself.3 Starting in 1980 several groups reported their surgical experiences in BSG surgery 
and classifications were introduced to display tumor types benefiting from surgery.4-8  
Besides histological classifications including malignant BSG – with a comparable dismal 
prognosis to other intracerebral high-grade gliomas – and low-grade BSG – with a more 
favorable course –morphological subtypes can be differentiated.5-7 For instance, two 
growth types of brainstem tumors, diffuse and circumscribed are described in the 
literature.6-8 In both types patients often present with incongruously minor deficits, even 
with large tumors, until the late stages of the illness, when the condition deteriorates 
rapidly.9 The mean age of diagnosis in BSG is 7-9 years, and there is no age or sex 
predilection.10, 11 A second peak appears at the fourth decade of age, however adult BSG 
are more uncommon and poorly understood with respect to prognostic factors.1, 12 
Since our department was one of the first hospitals worldwide, which treated BSG 
surgically we were interested in the paradigm changes of BSG surgery over the last 
decades and the long term follow-up of the operated patients. To provide a more 
consistent and comparable analysis about BSG surgery we included only patients with an 
available histopathological diagnosis and patients with low-grade gliomas (LGG) to provide 
long-term outcome data after BSG surgery.  
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3. Patients and Methods 
Three chairmen presided over the Department of Neurosurgery at the University 
Hospital Zurich between 1937 and 2007 and performed surgery on BSG, which were 
included in this study: H. Krayenbühl (1937 - 1973), G. Yasargil (1973 - 1993) and Y. 
Yonekawa (1993 - 2007). Analyzing all patient records that have been operated on BSG at 
the Department of Neurosurgery at the University Hospital Zurich, I included only patients 
with 1) a histopathological diagnosis and 2) with the diagnosis of a LGG to the final 
analysis. Patients, which underwent biopsy only, were excluded. Patients in the era before 
CT or MRI, but with histopathology were included in this study. The retrospective data 
collection for this study was approved by the Institutional Review Board Zurich (KEK 2011-
0069/3). Data concerning patient characteristics, tumor pathology and tumor location was 
obtained from the following sources: 
1. The hardcopy archive of the Department of Neurosurgery. Patients’ names from 
1937 – 1997 are sorted according to tumor location. 
2. The digitized surgery registry of the Department of Neurosurgery (in-house 
database) from 1996 – 2007. 
3. The digitized patient records of the University Hospital Zurich from 1990 – 2007. 
Patients search was based on ICD-10 codes that included C71-7 (neoplasm of the 
brainstem). 
4. The tumor data base of the Institute of Neuropathology (1982 – 2007) 
 
For overall survival (OS) analysis I collected data from the community registration 
offices of the largest municipalities of the patient recruitment area (Zurich, Winterthur, 
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Buelach and Uster). Histological diagnosis of the patients was obtained from the database 
of the Institute of Neuropathology, University Hospital Zurich for this study.   
The surgeries were grouped with respect to the eras of the directors of the clinic: 
Krayenbühl (1937 - 1973), Yasargil (1973 - 1993) and Yonekawa (1993 - 2007). The data 
was analyzed and displayed with the program package MATLAB (www.mathworks.com). 
The equality of medians was tested by the Wilcoxon rank sum test, the cross-tabulation by 
chi2 test. Statistical significance was assumed for p<0.05. 
 
4. Results 
Low-grade brainstem glioma patients 
Out of the 88 patients with available histopathology, there were 64 low-grade glioma (73%) 
patients including 35 male (54.7%) and 29 (45.3%) female patients with a median age of 
19 years (mean 20.8, range 3-44) and a high proportion of children (age<16y) (n=25, 
39%). Histopathological examination showed 55 low-grade astrocytomas (WHO grade I-II), 
4 oligodendrogliomas, 2 ependymomas, 2 gangliogliomas and 1 oligoastrocytoma. A 
higher percentage of low-grade BSG were operated in the era Yasargil compared to the 
era Yonekawa (53/77 vs. 13/27, cross-tabulation chi2 p=0.055) and the most common 
tumor localization of the low-grade BSG was the pons in 28 cases (43.8%) and the 
mesencephalon in 27 cases (42.2%) followed by the medulla oblongata in 9 cases (14%). 
Loss to follow-up (FU) included 17 patients (26.6%) without any information after discharge 
of the patients after index surgery. Median last FU for the available 47 patients (73.4%) 
was 9 years (range 0-33years) including 18 patients (38%) with a follow-up longer than 10 
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years and 10 patients (21.3%) with a long-term follow-up over 20 years. (Figure 1) 
 
Figure 1. Cumulative long-term follow-up (Kaplan-Meier) for N = 64 patients with LGG grouped by 
era Yasargil and Yonekawa. There is no significant difference between both groups (p=0.5). The 
dot represents the only documented death in the Yasargil group.  
 
 
There was only one documented death 27 years after surgery. All other 46 patients were 
alive at last follow-up some with long term postoperative MRI (Figure 2).  
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Figure 2. Follow-up MRIs examples of three long-time survivors with pilozytic astrocytomas (WHO 
grade I) all operated by Prof. Yasargil. A: 44y/m patient with a right pontomesencephalic lesion 
operated via a right-sided retrosigmoidal approach (06/1986), last follow-up MRI 25years after 
surgery shows a complete resection without recurrence and a residual left-sided hemiparesis (M4). 
B: 24y/m patient with dorsal mesencephalic astrocytoma subtotal resected via an infratentorial 
supracerebellar approach (11/1985), tumor remnant stable on last follow-up MRI 26years after 
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surgery, without any neurological deficit. C: 18y/m patient with a left-sided ventro-lateral lesion in 
the medulla oblongata. Gross total resection via a suboccipital median approach (04/1992). Tumor 
recurrence occurred 01/1993, since then tumor size was stable without treatment until last follow-
up 19 years later. At last follow up the patient was without neurological deficits.   
 
 
The survival status of the 17 patients, which were lost to follow-up after discharge, was 
unknown. Median progression free survival (PFS) of the 47 patients was 27 years with no 
significant difference between patients operated in the era Yonekawa (median PFS 6 
years) or Yasargil (median PFS 27 years) (Figure 3). Recurrence or progression of a tumor 
rest was present in 29.4% patients (10/34) of the Yasargil group and in 30.8% patients 
(4/13) of the Yonekawa group.  
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Figure 3. Progression-free survival (PFS) (Kaplan-Meier) for N = 64 patients with LGG grouped by 
era Yasargil (median PFS 27 years) and Yonekawa (median PFS 6 years).  
 
There is no significant difference between both groups (p=0.387). Patients with no 
progression at last follow-up were censored. 
 
Overall brainstem glioma patients 
Including all brainstem surgeries 124 surgeries in 124 patients (68 male, 55%) were 
found in the data collection including 4 patients in the era Krayenbühl (4%), 77 patients in 
the era Yasargil (71%), and 27 patients in the era Yonekawa (25%) (Figure 4A). In 88 
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cases tumor histology of the glioma pathology group could be further specified. Median 
age was 20 years (mean 25, range 2-77years, n=104) with a median age of 18 years 
(range 3-64 years) in the era Yasargil and 30 years (range 2-77 years) in the era 
Yonekawa (p=0.02). Overall, 36% (n=37) of the patients were children (<16years) (Figure 
4B and C), with a higher representation in the low-grade group (n=25/64, 39%) compared 
to the non low-grade group (n=12/40, 30%).  
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Figure 4. A Frequency of brain stem glioma surgeries. Era Yasargil (1973 - 1993) and era 
Yonekawa (1993 - 2007). B Age of each patient at surgery. C Age-distribution at surgery. 
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5. Discussion 
As the most striking result we present here that survival after surgery for brainstem 
glioma may last for decades. This result is based on a BSG surgery series spanning 44 
years from one of the first neurosurgical centers introducing microsurgery of the skull base. 
The pioneering work initiated by Dr. Krayenbühl and Dr. Yasargil and continued by Dr. 
Yonekawa stimulated neurosurgeons during their era until now.13 In the Zurich BSG series 
a large number of patients were treated by Dr. Yasargil and – to a lesser extent – by Dr. 
Yonekawa. Children constitute a large portion of the patients operated on, especially in the 
LGG group, which is in concordance with the incidence peak in the current literature.2, 14-16 
Interestingly, the median patient age at surgery was significantly lower in the cohort of Dr. 
Yasargil than in the cohort of Dr. Yonekawa, which displays a more balanced age 
distribution (Figure 4C).  An explanation for these findings might be found by the fact that 
in the beginning of the BSG surgery era patients and especially children were mainly 
operated to confirm the diagnosis and as a therapy modality itself. With novel imaging 
modalities such as MRI and a more detailed understanding in natural history and outcome 
of these lesions, the availability of treatment strategies for BSG changed over the last 
decades.17, 18 For instance, diffuse intrinsic BSG are nowadays not recommended to be 
primarily surgically resected or biopsied, since surgery does not alter the treatment 
strategy.18, 19 Based on modern MRI sequences, which allow a specific diagnosis of these 
lesions, the large group of diffuse intrinsic BSG are mainly treated conservatively with 
radiation therapy or chemotherapy.20 Only a small amount of BSG (10-15%) needs to be 
surgically treated such as in the presence of a focal, enhancing mass in the midbrain, 
medulla, or peduncle, or the presence of a dorsally exophytic tumor protruding into the 4th 
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ventricle.17 These results, therefore, reflect the changes in therapy management of BSG 
over the last decades. 
Comparing the histopathological findings of the BSG between the era of Yasargil 
and Yonekawa confirm the paradigm change in the therapy management of BSG. While a 
large part of LGG patients were operated by Prof Yasargil (80%), LGG were only a small 
part of all surgically received BSG histology in the following decades. After the introduction 
of MRI these low-grade lesions could be detected more specific by imaging and a biopsy 
or surgery would not alter further therapy strategy. However, a recently published meta-
analysis on stereotactic biopsies of brainstem tumors showed the importance of a present 
histology before adjuvant treatment, since more than 8% of patients were diagnosed with a 
nonneoplastic disease.21 Therefore, a biopsy might be recommended to ensure the 
assumed histology by MRI. 
The age distribution of the surgical treated adult patients, however, does not display 
the second peak at the fourth decade as reported for the incidence of BSG diagnosis. 
(Figure 4C)1 This may indicate that adults are subjected to neurosurgical treatment at a 
lower rate than children in general. These lesions account for only 1%-2% of intracranial 
gliomas in adults.22 
The BSG – both LGG and non LGG – in this data set were mainly located in the pons and 
mesencephalon, which is in concordance with the literature.2, 20, 23 With regards to outcome 
73.4% of the LGG patients could be followed-up after discharge with long-term FU 
including a high overall survival. The median FU was 9 years including a high percentage 
of patients with decadal FU (Figure 1). There was only one documented death 27 years 
after surgery and all other 46 patients were alive at last follow-up, which is compared to the 
literature.20, 24 Also the median PFS of 27 years is comparable with the literature (Figure 2). 
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Klimo et al. reported a PFS of 25.1 years in their study in 51 surgically treated brainstem 
LGG.24  
 As a limitation of this study, which retrospectively analyzed patient records 
over the last 4 decades, information on individual patient parameters is scarce. Several of 
the patients were operated on before the advent of diagnostic tools like MRI and dramatic 
changes in operative instrumentation and technology took place over the 4 decades time 
span such as intraoperative neuromonitoring. Also, FU was available for only a small 
number of patients. This could be improved by a nation-wide death registry and/or a 
prospective patient registry. Also the patient number and information at last FU was too 
small to further analyze tumor relapse or to obtain reliable OS data. On the other hand, our 
retrospective analysis enabled us to study BSG surgery over a time span of 4 decades to 
trace paradigm changes in BSG surgery.  
 
6. Conclusions 
In this study we were able to demonstrate long-term FU with a high overall survival 
and progression free survival in LGG patients after BSG surgery. As the University 
Hospital of Zurich was among the first to initiate BSG surgery, we could trace the 
paradigms of BSG surgery from its onset in a single center study.  
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